BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
Citi
AstraZeneca
Julphar
Express Scripts
Teva
Covington
Fish and Richardson
Novartis

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,814,953

« Back to Dashboard

Summary for Patent: 6,814,953
Title: Bronchodilating compositions and methods
Abstract:Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
Inventor(s): Banerjee; Partha S. (Davis, CA), Pham; Stephen (Sacramento, CA), Akapo; Samuel O. (Vacaville, CA), Chaudry; Imtiaz A. (Napa, CA)
Assignee: Dey L.P. (Napa, CA)
Application Number:10/138,866
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Drugs Protected by US Patent 6,814,953

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion BROVANA arformoterol tartrate SOLUTION;INHALATION 021912-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA ➤ Subscribe
Mylan Speclt PERFOROMIST formoterol fumarate SOLUTION;INHALATION 022007-001 May 11, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,814,953

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,667,344 Bronchodilating compositions and methods ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,814,953

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002244211 ➤ Subscribe
Canada 2438544 ➤ Subscribe
European Patent Office 1381346 ➤ Subscribe
Spain 2554476 ➤ Subscribe
Japan 2004532217 ➤ Subscribe
Japan 2009046490 ➤ Subscribe
Japan 2013155208 ➤ Subscribe
Japan 2015178506 ➤ Subscribe
Japan 6214925 ➤ Subscribe
Portugal 1381346 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Fuji
Merck
Dow
Medtronic
Chubb
QuintilesIMS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot